PGPatricia E. Gallardo

Patricia E. Gallardo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patricia E. Gallardo has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Adriana Varón

    Fundación Cardioinfantil

    1 shared publication
  • Alberto E. Muñoz

    Sección de Hepatología, Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Facultad de Medicina, Universidad de Buenos Aires. ; Instituto de Investigaciones en Salud Pública, Facultad de Odontología, Universidad de Buenos Aires. Ciudad Autónoma de Buenos Aires, Argentina

    1 shared publication
  • Alejandro Di Sibio

    National Cancer Institute of Argentina, Buenos Aires, Argentina

    1 shared publication
  • Alejandro Ferrada

    Instituto Chileno Japonés de Enfermedades Digestivas Hospital San Borja Arriaran Santiago Chile

    1 shared publication
  • Alejandro Soza

    Department of Gastroenterology, Faculty of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile

    1 shared publication
  • Amr S. Soliman

    Department of Community Health and Social Medicine, City University of New York School of Medicine, New York, NY, USA.

    1 shared publication

Latest Publications

  • Open Access

    Argentina’s National Program for Control of Breast Cancer: Time 1, Patient Navigation, and Patient Cancer Education Experience

    by Dora Valencia, Paula Granda, Veronica Pesce, Alejandro Di Sibio, Amr S. Soliman, Jorge Gómez, Irma Ramos, Patricia Gallardo

    Argentina has the second highest mortality rate for breast cancer (BC) in South America. The age-standardized incidence of BC in Argentina is 73 per 100,000. Despite the availability of early detection services, 30% of BCs are diagnosed at advanced disease stages. The National Cancer Institute (NCI) of Argentina and the National Program for Control of Breast Cancer (NPCBC) focus on two main objectives: guaranteeing adequate and timely BC treatment and reducing BC mortality in Argentina. These objectives are addressed by maintaining three core concepts: quality control, disease monitoring, and wide coverage of available early detection and treatment services. The NPCBC is currently implementing the “Time 1 Survey Study.” Time 1 is defined as the time from the first appearance of BC signs or symptoms to the first consult within the public healthcare system. This timeframe is important in Argentina because it is outside of the health timeframes and data parameters monitored by the national cancer data registry system. The Time 1 Survey study has the potential to serve as an informational tool for BC patient navigation efforts in Argentina because it can be used to identify and characterize the barriers and delays that women face during Time 1. Lessons and experiences included in this study could be translated to other Latin American and middle-income countries for developing cancer control programs that can lead to improving treatment and reducing mortality through patient navigation and cancer education efforts for the public, health professionals, and patients.


  • Open Access

    Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV‐infected patients in a real‐life cohort from Latin America

    by Manuel Mendizabal, Leila Haddad, Patricia E. Gallardo, Alejandro Ferrada, Alejandro A. Soza, Raul Adrover, Edmundo Aravena, Juan P. Roblero, Jhon Prieto, Claudia Vujacich, et al.

    Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real‐clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV therapy in real‐world setting. We analyzed a cohort of patients with genotype 1 infection treated with OBV/PTV/r/DSV ± RBV. Data on demographics, clinical features, safety, and virological response were retrospectively collected from 21 centers in Latin America. A total of 96 patients received OBV/PTV/r/DSV, associated with RBV in 68% of the cases. Most were genotype 1b (80%), 56 (58%) had cirrhosis, and 45 (47%) failed prior HCV treatment. Adverse events occurred in 62% of patients. The most common adverse events were pruritus (21%), hyperbilirubinemia (17%), and asthenia (17%). Five patients discontinued therapy prematurely due to hepatic decompensation, three of them were Child‐Pugh B at baseline and one patient died due to multi‐organ failure. Follow up HCV‐RNA 12 weeks after completion of therapy was evaluated in all the patients and sustained virologic response rate was 97%. No virologic breakthrough was detected. Our study confirms that OBV/PTV/r/DSV treatment is highly effective in patients with chronic HCV without cirrhosis or with Child‐Pugh A cirrhosis in non‐European populations. Adverse events were often mild and rarely led to treatment discontinuation except for patients with Child‐Pugh B cirrhosis or with previous history of hepatic decompensation. These results can support the development of public strategies to expand the access of OBV/PTV/r + DSV and other DAAs combinations in order to reduce the burden of HCV infection in our region.